Biogen's Aducanumab And Three Other Drugs Get First EU PRIME Designations
The European Medicines Agency has announced the names of the first four drugs to be accepted onto its new priority medicines scheme, including Biogen Inc.'s aducanumab for Alzheimer's disease. But the agency also turned down 14 other applications for PRIME eligibility.
You may also be interested in...
Gilead Science Inc. was slammed with a pair of attacks against the way it markets its hepatitis C virus (HCV) drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) and its HIV/AIDS medicines containing tenofovir – with one punch coming from a new foe, the Massachusetts Attorney General Maura Healey, and the other from one of its longtime antagonists, the AIDS Healthcare Foundation (AHF).
Biogen Inc. has earmarked $100m for business development in 2016, an investment the company hopes to take advantage of if the financial markets continue to be challenging for young biotechs, driving down valuations for assets.
EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”